FDA OKs new pancreatic cancer drug trialed at Dana-Farber

The FDA has expedited approval for daraxonrasib, a novel pancreatic cancer drug developed partly at Dana-Farber that targets a mutated protein in over 90% of cases, significantly extending patient survival compared to standard chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.